Nasdaq · Healthcare
MANNKIND CORP (MNKD)
As-reported financials and recent SEC filings for MANNKIND CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$349.0M
Net income
$5.9M
Net margin
1.7%
Diluted EPS
$0.02
ROE
-11.5%
P/E (TTM)
207.0×
Market cap
$1.28B
Debt / equity
-7.0×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $349.0M | $285.5M | $199.0M | $99.8M | $75.4M |
| Gross profit | — | — | $178.1M | $83.8M | $58.6M |
| Operating income | $38.8M | $72.6M | $8.7M | $-64.1M | $-47.0M |
| Net income | $5.9M | $27.6M | $-11.9M | $-87.4M | $-80.9M |
| Diluted EPS | $0.02 | $0.10 | $-0.04 | $-0.34 | $-0.32 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-02
View on EDGAR →8-K2026-05-28
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →Go deeper on MNKD
Search MANNKIND CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.